Top Tweets for #nmhspc
Macroscopic local relapse after RP in the context of high-risk #nmHSPC. Presentation by @PCaParker @royalmarsdenNHS. #EAU26 written coverage by @RKSayyid @UAUrology > https://t.co/ogdFusOcGv @Uroweb
🚩Do not miss these #CUA24 Educational Sessions featuring Brita Danielson, @UroOncMD, Christian Kollmannsberger, @wayne_brisbane, Bobby Shayegan, Hanmu Yan. 🚩Reserve your spot today >>> https://t.co/cMHALbepR4
#nmHSPC #prostatecancer #AI
🚩Do not miss these #CUA24 Educational Sessions featuring Brita Danielson, @UroOncMD, Christian Kollmannsberger, @wayne_brisbane, Bobby Shayegan, Hanmu Yan. 🚩Reserve your spot today >>> https://t.co/cMHALbdS1w
#nmHSPC #prostatecancer #AI
Global QOL was not meaningfully impacted by enzalutamide suspension in in patients with biochemically recurrent #nmHSPC responding well to enzalutamide, according to a data from the phase 3 EMBARK trial presented at #ASCO24. @SFreedlandMD @CSCancerCenter
https://t.co/FGnZyJ6K0g
The #ROAR study showed that #rucaparib had an acceptable safety & efficacy profile as an ADT-sparing approach in pts w/ high-risk biochemically recurrent #nmHSPC w/ #BRCA 1/2 or other homologous recombination repair mutations. @neerajaiims @maughanonc https://t.co/gtVZyJYzE5
経口アンドロゲン受容体阻害薬 #エンザルタミド について、生化学的再発のリスクが高い #非転移性去勢感受性前立腺がん（#nmCSPC、#nmHSPC）への適応拡大が米国で承認されました。
https://t.co/rXafTLL96A
Enzalutamide + leuprolide showed promise in patients with #nmHSPC with high-risk biochemical recurrence vs leuprolide alone, according to findings from the phase 3 EMBARK trial. #pcsm | @Dan_Theodorescu @CedarsSinaiMed
https://t.co/IzinhThhW8
#EMBARK: Health-related quality of life in #nmHSPC patients with high-risk BCR. Presentation by @SFreedlandMD @CedarsSinai. #ESMO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/Mu8gK3NFq1 @myESMO
PSMA PET findings in an “EMBARK-like” cohort of pts with high-risk #nmHSPC: a single center posthoc retrospective analysis. Presented by Wesley Armstrong @uclacaltechmstp. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/39xOmo58zi @ASCO
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMyWRM @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDIBcu @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEoaWJ @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMQxJk @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEFLOh @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/YlufsDI3mW @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK study: A phase 3 randomized study of enzalutamide + leuprolide and enzalutamide monotherapy in HR #nmHSPC with rising PSA after local therapy @SFreedlandMD @CSCancerCare. #WatchNow > https://t.co/19ihyEoaWJ @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
The #EMBARK Study: Phase 3 Randomized Study of Enzalutamide + Leuprolide and Enzalutamide Monotherapy in High-Risk #nmHSPC with Rising PSA after Local Therapy. #FullVideo on UroToday > https://t.co/lqQhrMzuHk @SFreedlandMD @pfizer @AstellasUS @UgoDeGiorgi @marty_gleave @BMJ_Open
Last Seen Hashtags on Sotwe
dreamybull
Seen from Brazil
teenagergirls() +filter:native_video
Seen from United States
esrarabiaünal
Seen from Turkey
amateurmilf
Seen from Switzerland
Jadenwalton
นวดรามอินทรา
Seen from Thailand
รับงานบางบ่อ
Seen from Thailand
Milky
Seen from Indonesia
cder
Seen from Indonesia
ometv
Seen from Singapore
Most Popular Users
Elon Musk 
@elonmusk
240.6M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.7M followers
Cristiano Ronaldo
@cristiano
110.6M followers
Narendra Modi
@narendramodi
107M followers
Rihanna
@rihanna
97.7M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
90.9M followers
KATY PERRY
@katyperry
87.7M followers
Taylor Swift
@taylorswift13
81.5M followers
Lady Gaga
@ladygaga
73.1M followers
Virat Kohli
@imvkohli
69.9M followers
Kim Kardashian
@kimkardashian
69.8M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
63.9M followers
Neymar Jr
@neymarjr
62.7M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.9M followers
X
@x
60.8M followers
Selena Gomez
@selenagomez
60.8M followers